So true. Look at AGIO today on its news. They are worth double what CLDX is. I find that valuation comparison to be comical given the pipeline of both.
My, still on CERS? Have you looked at CGEN? Doing some DD on them now.
Share, appreciate the the candid comments you make on CLDX. I get a sense that you look at CLDX with a skeptical eye. Is that correct? TY
Love the enthusiasm but these analyst is a shill. Has a $27 price target on SNTA and the stock is trading at $3.
Thanks. Any thoughts on today's Varli news?? I see 3 AE's but the rest appears to be positive. Need to really review it fully.
Myman, don't currently own this stock but I am impressed by your well thought out case for buying this stock.
Solid questions. Wonder if Oppy is angling for part of any potential secondary now the road. This analysis is not well thought out.
Your a nut, two hours ago you said that a CC after the close on the 14th was bad news. Now you say its "got to be good news"...... Liar liar.
I guess the other 3/4 threads you have written today about selling the firm was not enough for you???
Saw this article in US News and World Report Also. Dated 10/15/14:
WEDNESDAY, Oct. 15, 2014 (HealthDay News) -- An experimental immune-system therapy can often lead to complete remission in leukemia patients who have run out of other options, a new study confirms.
Researchers found that 27 of 30 children and adults with advanced acute lymphoblastic leukemia (ALL) went into full remission after receiving genetically tweaked versions of their own immune system cells.
"Ninety percent of patients who had no options left went into complete remission. That's amazing," said senior researcher Dr. Stephan Grupp, of Children's Hospital of Philadelphia and the University of Pennsylvania.
However, seven patients who went into remission did eventually suffer a relapse, according to the study.
The findings, published Oct. 16 in the New England Journal of Medicine, confirm what smaller studies have suggested: The therapy offers hope to people with ALL that has repeatedly eluded standard treatments.
But while past studies have focused on adults, this study included mostly children.
"It shows the therapy can work just as well in children with ALL, and it's great to see that," said Dr. Michel Sadelain, a researcher at Memorial-Sloan Kettering Cancer Center in New York City who worked on those earlier studies.
But, both Grupp and Sadelain said ongoing studies will have to clarify the therapy's role in treating ALL.
ALL is a cancer of the blood and bone marrow that progresses quickly. It's more common in children than adults, but while children are often cured with chemotherapy, adults have a poorer outlook, Sadelain said.
In the United States, about 6,000 people will be diagnosed with ALL this year, and just over 1,400 will die, according to the American Cancer Society (ACS). Adults will account for 80 percent of those deaths, according to the ACS.
The standard first treatment for ALL is three rounds of chemotherapy drugs, and for many patients that does beat back the cance